Table 2

Deep sequencing for IgH rearrangements before and after CD19 CAR-targeted T cell therapy. Adaptive Biotechnologies performed multiplex PCR and deep sequencing on genomic DNA prepared from BM aspirated on the noted day (see Supplementary Materials for further detail). Malignant IgH rearrangement refers to IgH rearrangements associated with the B-ALL tumor cells. Total numbers of IgH rearrangements are derived from both malignant and nonmalignant B cells.

Patient
ID
Day of
treatment
Total no.
of IgH
rearrangements
Total no. of
malignant IgH
rearrangements
MSK-
ALL01*
−157,48058
5515,9250
MSK-
ALL03*
−51,0840
3000
MSK-
ALL04
−42,430,0582,426,898
112,4071,316
241,144637
59995,5630
MSK-
ALL05*
−13,307,4943,300,732
81,8800
298,2700
MSK-
ALL06*
−34255,301174,698
185,4294
391,866,8510

*Patient has gone to allo-SCT and is off study.